India’s Sun Pharmaceutical Industries has announced a major Sun Pharma Organon acquisition, agreeing to buy U.S.-based Organon & Co. in an all-cash deal valued at USD 11.75 billion, including debt. The company will pay USD 14 per share to acquire...
Shares of Alembic Pharmaceuticals edged up 1.09 percent to Rs 772.55 after the company revealed plans to strengthen its global footprint with a new subsidiary in Southeast Asia. The move signals Alembic Pharmaceuticals’ continued push into...
Amneal Pharmaceuticals has announced a major acquisition deal worth up to $1.1 billion acquisition to acquire Kashiv BioSciences, strengthening its presence in the fast-growing biosimilars market. The move reflects the increasing focus among pharm...
Indian pharmaceutical company Lupin Limited has expanded its presence in the U.S. healthcare market with the launch of a diabetes medication after receiving approval from the United States Food and Drug Administration.
In an interview on “How India Built Pharma Industry Against All Odds,” Manish Sabharwal, Co-Founder of TeamLease Services, breaks down the rise of India’s pharmaceutical sector. He explores how a constrained economy and a tightly regulated...
India’s ammonia rule is tightening the availability of a key raw material for pharmaceutical companies, after the government directed that surplus ammonia from urea plants be reserved primarily for fertilizer production.
India’s healthcare landscape is undergoing a remarkable transformation, driven by a new generation of MedTech startups focused on developing affordable, high-quality medical technologies. With increasing demand for accessible healthcare solutions
India is facing a serious thalassemia drug shortage, prompting the government to seek an explanation from Novartis while exploring generic alternatives to stabilize supply. The issue centers on Desferal, a life-saving treatment used by...
Eli Lilly is in advanced discussions to acquire Kelonia Therapeutics in a deal valued at more than $2 billion, signaling a strong push into next-generation cancer treatments.
Piramal Pharma Solutions and Ajinomoto Bio-Pharma Services have entered into a strategic partnership to support the development and manufacturing of antibody-drug conjugates (ADCs), an emerging class of targeted cancer therap...
.jpg)
, CDSCO.jpg)